A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.
Advanced Breast Cancer
DRUG: SHR6390 Tablets|DRUG: Placebo Tablets|DRUG: Letrozole or Anastrozole Tablets
Investigator-assessed PFS, Investigator-assessed Progression Free Survival, Every 8 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, Up to approximately 24 months.
Progression-free Survival (PFS) per RECIST 1.1, PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first., Up to approximately 24 months|OS, Overall Survival, up to 2 years|ORR, Objective Response Rate, Up to approximately 24 months|DoR, Duration of Objective Response, Up to approximately 24 months|CBR, Clinical Benefit rate, Up to approximately 24 months|Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0, Number of Participants With adverse events and serious adverse events Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0, Up to approximately 24 months
Ctrough, To explore the pharmacokinetic characteristics of SHR6390 population and the influencing factors, Up to 4 weeks
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.